A phase 2 dose-escalation and double-blind efficacy study of ampreloxetine (TD-9855), a norepinephrine reuptake inhibitor, given once-daily to treat symptomatic neurogenic orthostatic hypotension

Authors
Category Primary study
ConferenceMovement Disorders Clinical Practice
Year 2020
This article has no abstract
Epistemonikos ID: a8094f348e736442d32996b74c42e3da2fbc10c0
First added on: Apr 30, 2026